Therapy-related myeloid neoplasms

Haematologica

Volumn 94, Issue 4, 2009, Pages 454-459

  Larson, Richard A ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b Department of the Hematologic Malignancies Clinical Research Program ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; GRANULOCYTE COLONY STIMULATING FACTOR; GYRASE INHIBITOR; MITOXANTRONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TENIPOSIDE;

ADOLESCENT; ADULT; AGED; ANEMIA; APOPTOSIS; BONE MARROW TUMOR; CELL TRANSPLANTATION; CHILD; CHROMOSOME ABERRATION; CYTOGENETICS; CYTOTOXICITY; DNA DAMAGE; EDITORIAL; ENZYME POLYMORPHISM; GENE MUTATION; HEMATOPOIETIC CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LEUKEMOGENESIS; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; PRESCHOOL CHILD; SCHOOL CHILD; STEM CELL; THERAPY RELATED MYELOID NEOPLASM; THROMBOCYTOPENIA;

ALKYLATING AGENTS; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; HUMANS; MYELOPROLIFERATIVE DISORDERS; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY;

EID: 66349111700     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2008.005157     Document Type: Editorial

References (24)

1. Godley LA, Larson RA. The syndrome of therapy-related myelodysplasia and myeloid leukemia. In: John M. Bennett, editor. The Myelodysplastic Syndromes. Pathobiology and Clinical Management. Marcel Dekker, New York. 2002. p. 139-76.
2. Offman J, Opelz G, Doehler B, Cummins D, Halil O, Banner NR, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 2004;104:822-8.
3. Rowley JD, Olney HJ. International workshop on the rela- tionship of prior therapy to balanced chromosome aberra- tions in therapy-related myelodysplastic syndromes and acute leukemia: overview report. Genes Chromos Cancer 2002;33:331-45.
4. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003; 102:43-52.
5. Vardiman JW, Arber DA, Brunning RD, Larson RA, Matutes E, Baumann I, Thiele J. Therapy-related myeloid neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Fourth Ed. Lyon, France: IARC Press, 2008. p. 127-9.
6. Larson RA, Wang Y, Banerjee M, Wiemels J, Hartford C, Le Beau MM, et al. Prevalence of the inactivating 609C->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999;94:803-7.
7. Allan JM, Wild CP, Rollinson S, Willett EV, Moorman AV, Dovey GJ, et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy- induced leukemia. Proc Natl Acad Sci USA 2001;98:11592-7.
8. Naoe T, Takeyama K, Yokozawa T, Kiyoi H, Seto M, Uike N, et al. Analysis of genetic polymorphism in NQO1, GST- M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 2000;6:4091-5.
9. Qian Z, Fernald AA, Godley LA, Larson RA, Le Beau MM. Expression profiling of CD34+ hematopoietic stem/pro- genitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci USA 2002; 99:14925-30.
10. Joslin JM, Fernald AA, Tennant TR, Davis EM, Kogan SC, Anastasi J, et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to development of myeloid disor- ders. Blood 2007;110:719-26.
11. Pedersen-Bjergaard J, Chistiansen DH, Desta F, Andersen MK. Alternative genetic pathways and cooperating genet- ic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2006;20:1943-9.
12. Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology Am Soc Hematology Education Program 2004:80-97.
13. Takeyama K, Seto M, Uike N, Hamajima N, Ino T, Mikuni C, et al. Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cyto- genetic features as well as prognostic factors. Int J Hematol 2000;71:144-52.
14. Kantarjian HM, Estey EH, Keating MJ. Treatment of thera- py-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am 1993;7:81-107.
15. Larson RA, Wernli M, Le Beau MM, Daly KM, Pape LH, Rowley JD, et al. Short remission durations in therapy- related leukemia despite cytogenetic compete responses to high-dose cytarabine. Blood 1988;72:1333-9.
16. Anderson JE, Gooley TA, Schoch G, Anasetti C, Bensinger WI, Clift RA, et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997;89:2578-85.
17. Yakoub-Agha I, de La Salmonière P, Ribaud P, Sutton L, Wattel E, Kuentz M, et al. Allogeneic bone marrow trans- plantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients - report of the French Society of Bone Marrow Transplantation. J Clin Oncol 2000;18:963-71.
18. Kroger N, Brand R, van Biezen A, Zander A, Dierlamm J, Niederwieser D, et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica 2009;94:542-49.
19. Kröger N, Brand R, van Biezen A, Cahn JY, Slavin S, Blaise D, et al. Autologous stem cell transplantation for therapy- related acute myeloid leukemia and myelodysplastic syn- drome. Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2006;37:183-9.
20. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analy- sis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004;18:120-5.
21. Kern W, Haferlach T, Schnittger S, Hiddemann W, Schoch C. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol 2004;22:2510-1.
22. Beaumont M, Sanz M, Carli PM, Maloisel F, Thomas X, Detourmignies L, et al. Therapy-related acute promyelo- cytic leukemia. J Clin Oncol 2003;21:2123-7.
23. Andersen MK, Larson RA, Mauritzson N, Schnittger S, Jhanwar SC, Pedersen-Bjergaard J. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an International Workshop. Genes Chromosomes Cancer 2002;33:395-400.
24. Slovak ML, Bedell V, Popplewell L, Arber DA, Schoch C, Slater R. 21q22 balanced chromosome aberrations in ther- apy-related hematological disorders: report from an International Workshop. Genes Chromosomes Cancer 2002;33:379-94.